Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 3/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.46 |
| ▸ | JAK2 | O60674 | 8/20 | 0.43 |
| ▸ | JAK3 | P52333 | 8/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | JAK1 | P23458 | 2/20 | 0.43 |
| ▸ | MTOR | P42345 | 3/20 | 0.41 |
| ▸ | ATM | Q13315 | 2/20 | 0.39 |
| ▸ | ATR | Q13535 | 2/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.38 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28908346 | 0.88 | ADORA3 (0.45) | CHRM2CHRM4CHRM1JAK2JAK3 | |
| SCHEMBL23216993 | 0.84 | ALDH1A1 (0.40) | CHRM2CHRM4CHRM1OPRM1 | |
| SCHEMBL30866992 | 0.79 | RPS6KA5 (0.43) | JAK2JAK3KCNH2JAK1TLR7 | |
| SCHEMBL18289975 | 0.79 | RPS6KA5 (0.43) | JAK2JAK3KCNH2JAK1TLR7 | |
| SCHEMBL18818255 | 0.79 | RPS6KA5 (0.43) | JAK2JAK3KCNH2JAK1TLR7 | |
| SCHEMBL25269666 | 0.77 | MTOR (0.44) | CHRM2CHRM4CHRM1JAK2JAK3 | |
| SCHEMBL25616566 | 0.76 | CHRM1 (0.44) | CHRM2CHRM4CHRM1JAK2JAK3 | |
| SCHEMBL29737109 | 0.75 | RXFP1 (0.34) | OPRM1 | |
| SCHEMBL30111811 | 0.74 | BTK (0.39) | JAK2JAK3JAK1TLR7OPRM1 | |
| SCHEMBL18285554 | 0.74 | BTK (0.45) | JAK2JAK3JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192691-A1 | HETEROCYCLIC COMPOUNDS AS BTK INHIBITORS | BEIJING INNOCARE PHARMA TECH CO LTD (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230192691-A1 | HETEROCYCLIC COMPOUNDS AS BTK INHIBITORS | BEIJING INNOCARE PHARMA TECH CO LTD (CN) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192691-A1 | HETEROCYCLIC COMPOUNDS AS BTK INHIBITORS | BTK, SYK, LYN | CHRM2 4242/4885CHRM4 4233/4885CHRM1 3604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.